Elite in Sickle Cell Disease

Dr. Lakshmanan Krishnamurti

Hematology | Oncology
1405 Clifton Rd Ne, 
Atlanta, GA 
Accepting New Patients
Elite in Sickle Cell Disease
1405 Clifton Rd Ne, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lakshmanan Krishnamurti is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Krishnamurti is rated as an Elite provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

His clinical research consists of co-authoring 119 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 105 articles and participated in 2 clinical trials in the study of Sickle Cell Disease.

Specialties
Hematology
Oncology
Licenses
Specialist in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

1405 Clifton Rd Ne, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Enrollment Status: Completed
Publish Date: December 14, 2023
Intervention Type: Genetic
Study Drug: BCL11A-Positive CD34-Positive Hematopoietic Stem Cells
Study Phase: Phase 1/Phase 2
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Efficacy of a Decision Aid for Hydroxyurea(HU) in Sickle Cell Disease(SCD)
Efficacy of a Decision Aid for Hydroxyurea(HU) in Sickle Cell Disease(SCD)
Enrollment Status: Terminated
Publish Date: July 23, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

119 Total Publications

The Pediatric Clinician's Approach to Referring Children and Adolescents with Sickle Cell Disease for Potentially Curative Therapies.
The Pediatric Clinician's Approach to Referring Children and Adolescents with Sickle Cell Disease for Potentially Curative Therapies.
Journal: Pediatric clinics of North America
Published: November 09, 2025
Similar Doctors
Abdullah Kutlar
Elite in Sickle Cell Disease
Dr. Abdullah Kutlar
Hematology Oncology | Hematology | Oncology
Elite in Sickle Cell Disease
Dr. Abdullah Kutlar
Hematology Oncology | Hematology | Oncology

Wellstar Medical Group LLC

5150 Stilesboro N W Rd, Suite 220, 
Kennesaw, GA 
 (25.9 miles away)
770-424-8222
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdullah Kutlar is a Hematologist Oncology specialist and a Hematologist in Kennesaw, Georgia. Dr. Kutlar is rated as an Elite provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Kutlar is currently accepting new patients.

Fuad E. Rassi
Distinguished in Sickle Cell Disease
Dr. Fuad E. Rassi
Hematology
Distinguished in Sickle Cell Disease
Dr. Fuad E. Rassi
Hematology

Emory Hemophilia Of Georgia

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (3.7 miles away)
404-778-1900
Experience:
20+ years
Languages Spoken:
English, Arabic, French
See accepted insurances
Offers Telehealth

Fuad Rassi is a Hematologist in Atlanta, Georgia. Dr. Rassi has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobin C Disease, Hemoglobin E Disease, and Hemoglobinopathy.

Distinguished in Sickle Cell Disease
Dr. Satvir Singh
Hematology | Oncology
Distinguished in Sickle Cell Disease
Dr. Satvir Singh
Hematology | Oncology

Suburban Hematology Oncology Associates

1700 Tree Lane, Suite 490, 
Snellville, GA 
 (18.1 miles away)
770-979-2828
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Satvir Singh is a Hematologist and an Oncologist in Snellville, Georgia. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Drug-Induced Thrombocytopenia, Thrombocytopenia, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Singh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krishnamurti's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile